Selective R-cadherin antagonist and methods

Details Selective R-cadherin antagonist and methods Selective R-cadherin antagonist and methods

2008-09-02

2008-09-02

Tsang, Cecilia J. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

10836289

ABSTRACT:
An isolated peptide useful as a selective antagonist of mammalian R-cadherin comprises 3 to 30 amino acid residues, three contiguous residues of the peptide having the amino acid sequence Ile-Xaa-Ser; wherein Xaa is an amino acid residue selected from the group consisting of Asp, Asn, Glu, and Gln. Preferably Xaa is Asp or Asn. In one preferred embodiment the peptide is a cyclic peptide having 3 to 10 amino acid residues arranged in a ring. The selective R-cadherin antagonist peptides of the invention are useful for inhibiting the targeting of stem cells, such as endothelial precursor cells, to developing vasculature, for inhibiting R-cadherin mediated cellular adhesion, and for inhibiting retinal angiogenesis.

REFERENCES:
patent: 2002/0151681 (2002-10-01), Rosen et al.
patent: 2006/0057135 (2006-03-01), Briskin et al.
patent: WO 96/24673 (1996-08-01), None
Magdolen, Viktor, et al, “Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87),” Biological Chemistry (2001), 382(8), 1197-1205.

Affiliated with

Also associated with

Rating

Selective R-cadherin antagonist and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selective R-cadherin antagonist and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective R-cadherin antagonist and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3934675